Interview With Rabbi Zac Kamenetz
Founder and CEO of Shefa, and Co-Founder of the Jewish Psychedelic Summit, Rabbi Zac Kamenetz, speaks about the upcoming summit and the connection between Judaism and psychedelics.
Founder and CEO of Shefa, and Co-Founder of the Jewish Psychedelic Summit, Rabbi Zac Kamenetz, speaks about the upcoming summit and the connection between Judaism and psychedelics.
CEO of Silo Wellness, Douglas K. Gordon, speaks about the company’s expansion to the Frankfurt Exchange and the recent collaboration with the Bob Marley Estate.
New research points to a connection between psilocybin mushrooms and creativity.
Former Texas Governor, the Republican Rick Perry, is supporting legislation for psychedelic therapy to help veterans with PTSD.
The first study of its kind compares psilocybin and the antidepressant Lexapro in treating depression. The results are promising.
April 19th is Bicycle Day — the first documented case of a human experience on LSD taken by chemist Albert Hoffman.
Digital Therapeutics and Psychedelic Medicines || MindMed’s SECRET WEAPON?!? MindMed (MMED / MMEDF / MMQ) and Atai’s secret weapon lies in the digitalization of psychedelic medicines. MindMed has Albert, their Digital Medicines division, and Atai has their Brain Computer Interface.
Instead of doing our usual “This Week In Psychedelic Stocks episode”, I decided to discuss the article entitled “Digital Therapeutics: Optimizing Psychedelics Therapies With Next-Generation IP” as it pertains to MindMed and Atai and because there wasn’t a lot of interesting news for our usual Psychedelic segment.
Why should investors in psychedelic stocks be deeply interested in these technological advancements? According to Jeff Nielson, there’s two reasons.
1.Generally, next-generation digital technology (which includes the introduction of AI) is already pioneering a tech revolution in healthcare.
2.Specifically, psychedelics-based therapies are one of the areas of medical treatment that will benefit the most from this technology.
I hope you guys found some value in this and I’ll keep you posted for more changes!
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
If you wish to collaborate, send us an email at:
thepsychedelicinvestor@gmail.com
Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
Time Stamps:
0:00 – Intro
10:08 – Implications for MindMed and Atai
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
#MindMed #MindmedStock #MMEDNews
Stephen Murphy, Co-Founder of Prohibition Partners, chats about the upcoming PSYCH Investor Summit taking place on April 21, 2021.
This week in psychedelic business news:psilocybin’s genome sequencing explored, psychedelics meet artificial intelligence, and more.
Results Are OUT! Finally we see that psilocybin is MORE EFFECTIVE in treating depression than the commonly used SSRIS. This study, run by the Imperial College of London is the FIRST MAJOR STUDY directly comparing SSRI’s with psilocybin, the predominant method of treatment.
The data was released on the 14th of April. So yes, this psilocybin trial treating depression CRUSHED SSRIS!
The study had 59 patients with Major Depressive Disorder, 30 of whom took 2 doses of Psilocybin 3 weeks apart, and 29 of whom took an SSRI, and the results will have MASSIVE IMPLICATIONS throughout the psychedelic investing world.
Though the study’s primary research objective which was purely by how much depression declined using the Quids SR 16 test, EVERY OTHER MEASUREMENT, such as using other measuring methods, decreases in Suicide ideation and percentage of patients in remission were secondary research objectives.
And again, every secondary research objective heavily FAVORED psilocybin.
This will be major news for companies like Compass Pathways (CMPS) and MindMed (MMED / MMEDF / MMQ)
Link to study: https://www.nejm.org/doi/suppl/10.1056/NEJMoa2032994/suppl_file/nejmoa2032994_appendix.pdf
So that’s it for This Week in Psychedelic Stocks fellow psychedelic investors!
I hope you guys found some value in this and I’ll keep you posted for more changes!
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
If you want to collaborate shoot us an email at: thepsychedelicinvestor@gmail.com
Music: www.bensound.com
https://benzinga.grsm.io/jameshallifa
…
https://benzinga.grsm.io/thepsychedel
…
General thoughts. We’ve been covering decriminalization and legalization efforts for almost two months now and EVERY WEEK, we see a new state or city starting to understand that psychedelics may be beneficial to society and may be able to treat mental illnesses such as depression, anxiety, ADHD, etc. On top of that, every week, we see study after study releasing promising results on the benefits of psychedelics to treat such mental maladies. If this is not proof that the SHROOM BOOM is real, what is? As more studies are released, it’ll only become more clear that psychedelics such as psilocybin, MDMA, DMT, LSD, etc may be able to disrupt a TRILLION dollar industry and us psychedelic investors might as well extract two-fold benefits : a. getting massive returns on investment and b. contributing to make the world a better place.
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
#MindMed #psilocybin #shroomboom
End of content
End of content
By signing up to the Psychedelic Spotlight newsletter you agree to receive electronic communications from Psychedelic Spotlight that may sometimes include advertisements or sponsored content.